Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
CPO107 is a bispecific fusion protein consisting ofatumumab, an anti-CD20 antibody, linked to signal regulatory protein alpha (SIRPalpha), which targets CD20 and CD47 expressed on tumor cells, potentially leading to antibody-dependent and complement-mediated tumor cell cytotoxicity and increased tumor cell phagocytosis and anti-tumor T-cell response (NCI Drug Dictionary).
|DrugClasses||CD20 Antibody 17 CD47 Antibody 25|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|